8-K: Inhibikase Therapeutics Announces Positive Preliminary Outcomes from FDA Pre-NDA Meeting for IkT-001Pro

Inhibikase Therapeutics reports positive preliminary feedback from the FDA regarding the approval pathway for its drug candidate IkT-001Pro in blood and gastrointestinal cancers.

Summary

• Inhibikase Therapeutics had a pre-new drug application (NDA) meeting with the FDA on January 19, 2024, to discuss the approval pathway for IkT-001Pro, a prodrug of imatinib mesylate, for blood and gastrointestinal cancers.
• The FDA indicated that the 505(b)(2) pathway appears to be appropriate for IkT-001Pro approval, and the company plans to seek approval for all 11 indications for which imatinib mesylate is approved, including pediatric use.
• The FDA acknowledged that clinical studies suggest 600 mg and 800 mg of IkT-001Pro provide similar exposures to 400 mg and 600 mg of imatinib mesylate, respectively.
• The FDA advised that Inhibikase should evaluate additional doses of IkT-001Pro to ensure bioequivalence up to 800 mg, the highest approved dose of imatinib mesylate.
• The FDA also recommended evaluating potential differences in absorption between IkT-001Pro and imatinib mesylate in the gut.
• Inhibikase is conducting pre-clinical tests to ensure IkT-001Pro mimics imatinib mesylate in all respects.
• The company is also developing a comprehensive risk analysis to prevent mix-ups between IkT-001Pro and imatinib mesylate.
• Inhibikase is progressing its 201 Trial for risvodetinib in Parkinson's disease, with 51 participants enrolled and 23 completing the 12-week dosing period.

Sentiment

Score: 7

Explanation: The document presents positive preliminary feedback from the FDA and progress in clinical trials, but also highlights the need for further studies and potential risks. The overall sentiment is cautiously optimistic.

Positives

• The FDA's feedback on the 505(b)(2) pathway provides a clear regulatory path for IkT-001Pro.
• The company's plan to seek approval for all 11 indications of imatinib mesylate expands the potential market for IkT-001Pro.
• The bioequivalence data suggests that IkT-001Pro can achieve similar drug exposures to imatinib mesylate at higher doses.
• The company is proactively addressing potential absorption differences and mix-up risks between the two drugs.
• The 201 Trial for risvodetinib is progressing with a significant number of participants enrolled and completing the dosing period.
• Preclinical studies indicate IkT-001Pro is safer than imatinib.

Negatives

• The FDA has requested additional studies to evaluate the bioequivalence of IkT-001Pro at higher doses.
• The company needs to conduct further studies to assess potential differences in absorption between IkT-001Pro and imatinib mesylate.
• There is a need to develop a comprehensive risk analysis to prevent mix-ups between the two drugs.

Risks

• The FDA's formal review of the NDA package could differ from the preliminary feedback.
• The company may need to conduct additional clinical studies to gain approval for all indications.
• There is a risk that the pre-clinical tests may not confirm the bioequivalence of IkT-001Pro to imatinib mesylate.
• The company may face challenges in preventing mix-ups between IkT-001Pro and imatinib mesylate.
• The company's ability to secure commercialization partners and complete the NDA submission is uncertain.
• The company's ability to enroll and complete the 201 Trial for risvodetinib is subject to risks.

Future Outlook

The company plans to seek all 11 indications for which imatinib mesylate has been approved and will request milestone-based meetings with the FDA as it completes the manufacturing and quality control processes. The company will also continue to progress the 201 Trial evaluating risvodetinib in untreated Parkinsons disease.

Management Comments

• Dr. Milton Werner, President and Chief Executive Officer of Inhibikase, stated that they were pleased with the discussion with the FDA as they begin the process of building their first NDA package.
• Dr. Werner noted that there is significant work ahead as they discuss details with potential commercialization partners and carry out the work needed for the NDA submission.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly companies developing treatments for cancer and neurodegenerative diseases. The use of the 505(b)(2) pathway is a common strategy for companies seeking to bring new formulations of existing drugs to market. The focus on improving the safety and tolerability of existing treatments is also a key trend in the industry.

Comparison to Industry Standards

• The 505(b)(2) regulatory pathway is a common strategy for pharmaceutical companies seeking to gain approval for new formulations of existing drugs, such as IkT-001Pro, which is a prodrug of imatinib mesylate. This pathway allows companies to rely on existing safety and efficacy data, potentially reducing the time and cost of development compared to a traditional new drug application.
• Companies like Teva Pharmaceuticals and Mylan (now Viatris) have successfully used the 505(b)(2) pathway to bring generic and reformulated drugs to market. Inhibikase's approach is similar in that it seeks to improve upon an existing drug, imatinib, by developing a safer prodrug formulation.
• The focus on bioequivalence studies is also a standard practice in the pharmaceutical industry, with companies like Amgen and AbbVie conducting such studies to demonstrate that their biosimilar products are comparable to the reference products. Inhibikase's bioequivalence studies for IkT-001Pro are crucial for demonstrating that it delivers similar drug exposures to imatinib mesylate.
• The development of a comprehensive risk analysis to prevent mix-ups between IkT-001Pro and imatinib mesylate is also a standard practice in the pharmaceutical industry, with companies like Pfizer and Novartis implementing such measures to ensure patient safety. This is particularly important for drugs with similar names or appearances.

Stakeholder Impact

• Shareholders may view the positive FDA feedback as a positive development for the company's pipeline.
• Patients with blood and gastrointestinal cancers may benefit from a safer alternative to imatinib mesylate.
• Patients with Parkinson's disease may benefit from the continued progress of the risvodetinib trial.
• Potential commercialization partners may be interested in the company's progress with IkT-001Pro.

Next Steps

• Inhibikase will conduct additional studies to evaluate the bioequivalence of IkT-001Pro at higher doses.
• The company will conduct further studies to assess potential differences in absorption between IkT-001Pro and imatinib mesylate.
• Inhibikase will develop a comprehensive risk analysis to prevent mix-ups between the two drugs.
• The company will request milestone-based meetings with the FDA as it completes the manufacturing and quality control processes.
• Inhibikase will continue to progress the 201 Trial evaluating risvodetinib in untreated Parkinsons disease.

Key Dates

Keywords

IkT-001Pro, imatinib mesylate, FDA, 505(b)(2), bioequivalence, blood cancers, gastrointestinal cancers, Parkinson's disease, risvodetinib, NDA, Abelson Tyrosine Kinase